Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation reports developments in surgical robotics for urology, centered on its AQUABEAM and HYDROS Robotic Systems and Aquablation therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia. Company news commonly covers financial results, system sales and procedure trends, commercial execution, pricing and inventory commentary, and investment in its BPH platform technology.
Updates also include product clearances such as FirstAssist AI software, international launch activity for HYDROS, clinical evidence and guideline recognition for Aquablation therapy, investor presentations, and research activity including the WATER IV prostate cancer trial.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) will report its third-quarter 2021 financial results on November 4, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, accessible via phone or webcast. The company specializes in urological surgical robotics, focusing on the AquaBeam Robotic System, which treats benign prostatic hyperplasia (BPH), affecting approximately 40 million men in the U.S. PROCEPT has established a robust clinical foundation with nine studies and over 100 peer-reviewed publications supporting its Aquablation therapy.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced that Cigna will now cover Aquablation therapy for Benign Prostatic Hyperplasia (BPH), effective September 15, 2021. This decision enhances access to a proven treatment option for millions of Cigna members suffering from lower urinary tract symptoms (LUTS) due to BPH. CEO Reza Zadno emphasized that Aquablation therapy, which has demonstrated clinical efficacy irrespective of prostate size or shape, aligns with high-quality clinical data trusted by payors. Cigna joins Medicare and other private health plans in supporting this therapy.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has successfully closed its upsized initial public offering of 7,539,400 shares at a price of $25.00 per share, generating approximately $188.5 million in gross proceeds. This offering included the full exercise of underwriters' options for an additional 983,400 shares. Shares began trading on the Nasdaq Global Market on September 15, 2021. The offering was managed by BofA Securities and Goldman Sachs, among others. PROCEPT focuses on innovative solutions in urology, particularly the AquaBeam Robotic System for treating benign prostatic hyperplasia (BPH).
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has priced its upsized initial public offering at $25.00 per share, raising total gross proceeds of $163.9 million. The offering consists of 6,556,000 shares, all sold by PROCEPT, with trading on the Nasdaq expected to begin on September 15, 2021. The offering is scheduled to close on September 17, 2021, pending customary conditions. Underwriters have a 30-day option to purchase an additional 983,400 shares. PROCEPT is focused on developing robotic solutions for urology, particularly the AquaBeam Robotic System for treating benign prostatic hyperplasia.